What does Kalaris Therapeutics, Inc. do?
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular…
What is Kalaris Therapeutics, Inc.'s P/E and P/B ratio?
Kalaris Therapeutics, Inc. has a P/E ratio of -1.0 and a P/B ratio of 0.82.
What is Kalaris Therapeutics, Inc.'s debt-to-equity ratio?
Kalaris Therapeutics, Inc. has a debt-to-equity ratio of 0.02.
How much does Kalaris Therapeutics, Inc. owe compared with what it owns?
Kalaris Therapeutics, Inc. owes $0.42 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Kalaris Therapeutics, Inc.'s Positivity rank?
Kalaris Therapeutics, Inc. is ranked #1,207 of 6,774 companies globally and #243 of 4,000 in United States on PositoAI, with a Positivity Score of 23,079.
Does Kalaris Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Kalaris Therapeutics, Inc..
Where can I read the latest news about Kalaris Therapeutics, Inc.?
Recent headlines about Kalaris Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Kalaris Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Kalaris Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.